The potential acquisition of Syqe Medical by Phillip Morris represents a significant strategic move for the tobacco giant, signaling its entry into the flourishing marijuana industry. With an initial investment of $130 million to support Syqe’s FDA approval process, followed by a possible $650 million acquisition, this deal can potentially make Syqe one of the largest cannabis companies globally. Moreover, Syqe’s innovative inhaler, utilizing raw cannabis inflorescence, could secure FDA approval, positioning the company as a trailblazer in the medical cannabis sector.
New aggregated polls reveal that 55% of respondents believe marijuana is not dangerous, and a…
Every Croptober, growers waste time on folklore instead of physics. We break down the science…
Leafly's 2026 cannabis voter guide for the midterms is the only plan you need to…
Come along on an Emerald Triangle road trip with Lindsay MaHarry to see some of…
This month an Iowa church got what every sacramental-plant congregation dreams about: a path to…
The cannabis industry does not need another study, another tax revenue report, or another state-level…